Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32682484

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2020 Jul 18
First author
Dimopoulos M

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Jul 18;396(10245):147-148. doi: 10.1016/S0140-6736(20)30901-6.
    note
    Source null
    related pmid
    32682464
    relationship
    Comment in
  2. citation
    Lancet. 2020 Aug 15;396(10249):466. doi: 10.1016/S0140-6736(20)31669-X.
    note
    Source null
    related pmid
    32798488
    relationship
    Erratum in

Authors and identifiers

  1. name
    Dimopoulos M
    type
    Author
  2. name
    Quach H
    type
    Author
  3. name
    Mateos MV
    type
    Author
  4. name
    Landgren O
    type
    Author
  5. name
    Leleu X
    type
    Author
  6. name
    Siegel D
    type
    Author
  7. name
    Weisel K
    type
    Author
  8. name
    Yang H
    type
    Author
  9. name
    Klippel Z
    type
    Author
  10. name
    Zahlten-Kumeli A
    type
    Author
  11. name
    Usmani SZ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dimopoulos M
    type
    Author
  2. name
    Quach H
    type
    Author
  3. name
    Mateos MV
    type
    Author
  4. name
    Landgren O
    type
    Author
  5. name
    Leleu X
    type
    Author
  6. name
    Siegel D
    type
    Author
  7. name
    Weisel K
    type
    Author
  8. name
    Yang H
    type
    Author
  9. name
    Klippel Z
    type
    Author
  10. name
    Zahlten-Kumeli A
    type
    Author
  11. name
    Usmani SZ
    type
    Author
bibliography ids
  1. nci-bib-2693146090145dd2fcf348c3
book metadata
content sha256
f9b3b57668dfece3f6aadf0cb7b74e4ece15b53a846708acd715a730048ec427
document type
citation
dois
  1. 10.1016/S0140-6736(20)30734-0
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:32682484
immutable id
pubmed:32682484@f9b3b57668dfece3f6aadf0cb7b74e4ece15b53a846708acd715a730048ec427
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10245
name
Lancet (London, England)
nlm unique id
2985213R
pages
186-197
volume
396
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Jul 18;396(10245):147-148. doi: 10.1016/S0140-6736(20)30901-6.
    note
    Source null
    related pmid
    32682464
    relationship
    Comment in
  2. citation
    Lancet. 2020 Aug 15;396(10249):466. doi: 10.1016/S0140-6736(20)31669-X.
    note
    Source null
    related pmid
    32798488
    relationship
    Erratum in
outcomes validated
false
pmid
32682484
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
5d5033aa6508f5dc85a3314e7732ed5c82bc282418416d5d1eb9cca60ccc84d0
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Jul 18
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32682484/
title
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

Preserved source evidence · Not medical advice